ID   ENPP1_HUMAN             Reviewed;         925 AA.
AC   P22413; Q5T9R6; Q9NPZ3; Q9P1P6; Q9UP61; Q9Y6K3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   19-SEP-2002, sequence version 2.
DT   10-MAY-2017, entry version 190.
DE   RecName: Full=Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;
DE            Short=E-NPP 1;
DE   AltName: Full=Membrane component chromosome 6 surface marker 1;
DE   AltName: Full=Phosphodiesterase I/nucleotide pyrophosphatase 1;
DE   AltName: Full=Plasma-cell membrane glycoprotein PC-1;
DE   Includes:
DE     RecName: Full=Alkaline phosphodiesterase I;
DE              EC=3.1.4.1 {ECO:0000269|PubMed:8001561};
DE   Includes:
DE     RecName: Full=Nucleotide pyrophosphatase;
DE              Short=NPPase;
DE              EC=3.6.1.9 {ECO:0000269|PubMed:8001561};
DE     AltName: Full=Nucleotide diphosphatase {ECO:0000305};
GN   Name=ENPP1; Synonyms=M6S1, NPPS, PC1, PDNP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skin fibroblast;
RX   PubMed=2211644;
RA   Buckley M.F., Loveland K.A., McKinstry W.J., Garson O.M., Goding J.W.;
RT   "Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human
RT   molecule, amino acid sequence, and chromosomal location.";
RL   J. Biol. Chem. 265:17506-17511(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Skin fibroblast;
RX   PubMed=1315502; DOI=10.1016/0003-9861(92)90504-P;
RA   Funakoshi I., Kato H., Horie K., Yano T., Hori Y., Kobayashi H.,
RA   Inoue T., Suzuki H., Fukui S., Tsukahara M., Kajii T., Yamashina I.;
RT   "Molecular cloning of cDNAs for human fibroblast nucleotide
RT   pyrophosphatase.";
RL   Arch. Biochem. Biophys. 295:180-187(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Bozzali M., Pizzuti A., Trischitta E.;
RT   "Genomic structure of the human PC1 gene.";
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 145-185, AND VARIANT GLN-173.
RX   PubMed=10480624; DOI=10.2337/diabetes.48.9.1881;
RA   Pizzuti A., Frittitta L., Argiolas A., Baratta R., Goldfine I.D.,
RA   Bozzali M., Ercolino T., Scarlato G., Iacoviello L., Vigneri R.,
RA   Tassi V., Trischitta V.;
RT   "A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding
RT   region is strongly associated with insulin resistance.";
RL   Diabetes 48:1881-1884(1999).
RN   [7]
RP   SUBCELLULAR LOCATION, TOPOLOGY, CATALYTIC ACTIVITY, FUNCTION, AND
RP   GLYCOSYLATION.
RX   PubMed=8001561; DOI=10.1111/j.1432-1033.1994.tb20068.x;
RA   Belli S.I., Goding J.W.;
RT   "Biochemical characterization of human PC-1, an enzyme possessing
RT   alkaline phosphodiesterase I and nucleotide pyrophosphatase
RT   activities.";
RL   Eur. J. Biochem. 226:433-443(1994).
RN   [8]
RP   ACTIVE SITE.
RX   PubMed=7737162; DOI=10.1111/j.1432-1033.1995.tb20308.x;
RA   Belli S.I., Mercuri F.A., Sali A., Goding J.W.;
RT   "Autophosphorylation of PC-1 (alkaline phosphodiesterase I/nucleotide
RT   pyrophosphatase) and analysis of the active site.";
RL   Eur. J. Biochem. 228:669-676(1995).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=9344668; DOI=10.1006/geno.1997.4949;
RA   Piao J.-H., Goding J.W., Nakamura H., Sano K.;
RT   "Molecular cloning and chromosomal localization of PD-Ibeta (PDNP3), a
RT   new member of the human phosphodiesterase I genes.";
RL   Genomics 45:412-415(1997).
RN   [10]
RP   INTERACTION WITH INSR, AND FUNCTION IN INHIBITION OF INSR KINASE
RP   ACTIVITY.
RX   PubMed=10615944; DOI=10.2337/diabetes.49.1.13;
RA   Maddux B.A., Goldfine I.D.;
RT   "Membrane glycoprotein PC-1 inhibition of insulin receptor function
RT   occurs via direct interaction with the receptor alpha-subunit.";
RL   Diabetes 49:13-19(2000).
RN   [11]
RP   CHARACTERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=11598187; DOI=10.1091/mbc.12.10.3004;
RA   Bello V., Goding J.W., Greengrass V., Sali A., Dubljevic V.,
RA   Lenoir C., Trugnan G., Maurice M.;
RT   "Characterization of a di-leucine-based signal in the cytoplasmic tail
RT   of the nucleotide-pyrophosphatase NPP1 that mediates basolateral
RT   targeting but not endocytosis.";
RL   Mol. Biol. Cell 12:3004-3015(2001).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15072822; DOI=10.1016/j.canlet.2003.11.002;
RA   Yano Y., Hayashi Y., Sano K., Nagano H., Nakaji M., Seo Y.,
RA   Ninomiya T., Yoon S., Yokozaki H., Kasuga M.;
RT   "Expression and localization of ecto-nucleotide
RT   pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-
RT   NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic
RT   bile duct diseases.";
RL   Cancer Lett. 207:139-147(2004).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-341.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-341; ASN-643 AND ASN-748.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   STRUCTURE BY NMR OF 147-189.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the somatomedin B domain of human
RT   ectonucleotide pyrophosphatase/phosphodiesterase family member.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [17]
RP   VARIANTS OPLL PRO-91 AND PHE-287, AND VARIANTS GLN-173; HIS-268 AND
RP   PRO-779.
RX   PubMed=10453738; DOI=10.1007/s004390050993;
RA   Nakamura I., Ikegawa S., Okawa A., Okuda S., Koshizuka Y.,
RA   Kawaguchi H., Nakamura K., Koyama T., Goto S., Toguchida J.,
RA   Matsushita M., Ochi T., Takaoka K., Nakamura Y.;
RT   "Association of the human NPPS gene with ossification of the posterior
RT   longitudinal ligament of the spine (OPLL).";
RL   Hum. Genet. 104:492-497(1999).
RN   [18]
RP   VARIANT GACI1 PHE-579, AND VARIANT CYS-774.
RX   PubMed=12881724; DOI=10.1038/ng1221;
RA   Rutsch F., Ruf N., Vaingankar S., Toliat M.R., Suk A., Hohne W.,
RA   Schauer G., Lehmann M., Roscioli T., Schnabel D., Epplen J.T.,
RA   Knisely A., Superti-Furga A., McGill J., Filippone M., Sinaiko A.R.,
RA   Vallance H., Hinrichs B., Smith W., Ferre M., Terkeltaub R.,
RA   Nuernberg P.;
RT   "Mutations in ENPP1 are associated with 'idiopathic' infantile
RT   arterial calcification.";
RL   Nat. Genet. 34:379-381(2003).
RN   [19]
RP   VARIANTS GACI1 VAL-342 AND PHE-371.
RX   PubMed=15940697; DOI=10.1002/ajmg.a.30800;
RA   Cheng K.-S., Chen M.-R., Ruf N., Lin S.-P., Rutsch F.;
RT   "Generalized arterial calcification of infancy: different clinical
RT   courses in two affected siblings.";
RL   Am. J. Med. Genet. A 136:210-213(2005).
RN   [20]
RP   VARIANT GLN-173, AND INVOLVEMENT IN NIDDM.
RX   PubMed=16186408; DOI=10.2337/diabetes.54.10.3021;
RA   Bacci S., Ludovico O., Prudente S., Zhang Y.Y., Di Paola R.,
RA   Mangiacotti D., Rauseo A., Nolan D., Duffy J., Fini G., Salvemini L.,
RA   Amico C., Vigna C., Pellegrini F., Menzaghi C., Doria A.,
RA   Trischitta V.;
RT   "The K121Q polymorphism of the ENPP1/PC-1 gene is associated with
RT   insulin resistance/atherogenic phenotypes, including earlier onset of
RT   type 2 diabetes and myocardial infarction.";
RL   Diabetes 54:3021-3025(2005).
RN   [21]
RP   VARIANTS GACI1 LEU-250; TYR-252 DEL; THR-305; VAL-342 AND PHE-371, AND
RP   VARIANT CYS-774.
RX   PubMed=15605415; DOI=10.1002/humu.9297;
RA   Ruf N., Uhlenberg B., Terkeltaub R., Nurnberg P., Rutsch F.;
RT   "The mutational spectrum oENPP1 as arising after the analysis of 23
RT   unrelated patients with generalized arterial calcification of infancy
RT   (GACI).";
RL   Hum. Mutat. 25:98-98(2005).
RN   [22]
RP   VARIANTS GACI1 ARG-126; TYR-216; GLU-242; LEU-250; ASN-276; THR-305;
RP   VAL-342; LYS-349; PHE-371; GLN-456; CYS-471; TRP-481; PRO-500;
RP   ARG-504; CYS-513; CYS-570; PHE-579; CYS-659; ARG-726; ARG-777;
RP   SER-792; HIS-804 AND TRP-888, AND VARIANTS VAL-611; LYS-668; CYS-774
RP   AND HIS-821.
RX   PubMed=20016754; DOI=10.1161/CIRCGENETICS.108.797704;
RG   GACI Study Group;
RA   Rutsch F., Boeyer P., Nitschke Y., Ruf N., Lorenz-Depierieux B.,
RA   Wittkampf T., Weissen-Plenz G., Fischer R.J., Mughal Z., Gregory J.W.,
RA   Davies J.H., Loirat C., Strom T.M., Schnabel D., Nuernberg P.,
RA   Terkeltaub R.;
RT   "Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are
RT   associated with survival beyond infancy in generalized arterial
RT   calcification of infancy.";
RL   Circ. Cardiovasc. Genet. 1:133-140(2008).
RN   [23]
RP   VARIANT ARHR2 VAL-266.
RX   PubMed=20137773; DOI=10.1016/j.ajhg.2010.01.006;
RA   Lorenz-Depiereux B., Schnabel D., Tiosano D., Hausler G., Strom T.M.;
RT   "Loss-of-function ENPP1 mutations cause both generalized arterial
RT   calcification of infancy and autosomal-recessive hypophosphatemic
RT   rickets.";
RL   Am. J. Hum. Genet. 86:267-272(2010).
RN   [24]
RP   VARIANT ARHR2 SER-901, AND CHARACTERIZATION OF VARIANT ARHR2 SER-901.
RX   PubMed=20137772; DOI=10.1016/j.ajhg.2010.01.010;
RA   Levy-Litan V., Hershkovitz E., Avizov L., Leventhal N., Bercovich D.,
RA   Chalifa-Caspi V., Manor E., Buriakovsky S., Hadad Y., Goding J.,
RA   Parvari R.;
RT   "Autosomal-recessive hypophosphatemic rickets is associated with an
RT   inactivation mutation in the ENPP1 gene.";
RL   Am. J. Hum. Genet. 86:273-278(2010).
RN   [25]
RP   VARIANT GLN-173.
RX   PubMed=20034067; DOI=10.1002/ajmg.a.33162;
RA   Le Boulanger G., Labreze C., Croue A., Schurgers L.J., Chassaing N.,
RA   Wittkampf T., Rutsch F., Martin L.;
RT   "An unusual severe vascular case of pseudoxanthoma elasticum
RT   presenting as generalized arterial calcification of infancy.";
RL   Am. J. Med. Genet. A 152:118-123(2010).
RN   [26]
RP   VARIANT GACI1 VAL-218.
RX   PubMed=23430823; DOI=10.1007/8904_2011_11;
RA   Galletti S., Nitschke Y., Malavolti A.M., Aquilano G., Faldella G.,
RA   Corvaglia L., Rutsch F.;
RT   "Generalized arterial calcification of infancy: fatal clinical course
RT   associated with a novel mutation in ENPP1.";
RL   JIMD Rep. 1:23-27(2011).
RN   [27]
RP   VARIANTS GACI1 HIS-538 AND ARG-586.
RX   PubMed=22209248; DOI=10.1016/j.ajhg.2011.11.020;
RA   Nitschke Y., Baujat G., Botschen U., Wittkampf T., du Moulin M.,
RA   Stella J., Le Merrer M., Guest G., Lambot K.,
RA   Tazarourte-Pinturier M.F., Chassaing N., Roche O., Feenstra I.,
RA   Loechner K., Deshpande C., Garber S.J., Chikarmane R., Steinmann B.,
RA   Shahinyan T., Martorell L., Davies J., Smith W.E., Kahler S.G.,
RA   McCulloch M., Wraige E., Loidi L., Hohne W., Martin L., Hadj-Rabia S.,
RA   Terkeltaub R., Rutsch F.;
RT   "Generalized arterial calcification of infancy and pseudoxanthoma
RT   elasticum can be caused by mutations in either ENPP1 or ABCC6.";
RL   Am. J. Hum. Genet. 90:25-39(2012).
RN   [28]
RP   VARIANTS COLED SER-149; SER-164 AND TYR-177.
RX   PubMed=24075184; DOI=10.1016/j.ajhg.2013.08.007;
RA   Eytan O., Morice-Picard F., Sarig O., Ezzedine K., Isakov O., Li Q.,
RA   Ishida-Yamamoto A., Shomron N., Goldsmith T., Fuchs-Telem D., Adir N.,
RA   Uitto J., Orlow S.J., Taieb A., Sprecher E.;
RT   "Cole disease results from mutations in ENPP1.";
RL   Am. J. Hum. Genet. 93:752-757(2013).
RN   [29]
RP   VARIANTS ARHR2 ASP-92; ARG-219 AND SER-792, AND INVOLVEMENT IN ARHR2.
RX   PubMed=25741938; DOI=10.1515/jpem-2014-0531;
RA   Steichen-Gersdorf E., Lorenz-Depiereux B., Strom T.M., Shaw N.J.;
RT   "Early onset hearing loss in autosomal recessive hypophosphatemic
RT   rickets caused by loss of function mutation in ENPP1.";
RL   J. Pediatr. Endocrinol. Metab. 28:967-970(2015).
RN   [30]
RP   VARIANTS COLED ARG-133 AND SER-177.
RX   PubMed=26617416; DOI=10.1111/bjd.14328;
RA   Schlipf N.A., Traupe H., Gilaberte Y., Peitsch W.K., Hausser I.,
RA   Oji V., Schmieder A., Schneider S.W., Demmer P., Roesler B.,
RA   Fischer J.;
RT   "Association of Cole disease with novel heterozygous mutations in the
RT   somatomedin-B domains of the ENPP1 gene: necessary, but not always
RT   sufficient.";
RL   Br. J. Dermatol. 174:1152-1156(2016).
RN   [31]
RP   VARIANTS GACI1 ARG-195; SER-195 AND CYS-301, CHARACTERIZATION OF
RP   VARIANTS GLN-173; LYS-668; CYS-774 AND HIS-821, CHARACTERIZATION OF
RP   VARIANTS GACI1 ARG-195; SER-195; CYS-301; THR-305; CYS-471; ARG-504;
RP   CYS-513; HIS-538; ARG-586; CYS-659; ARG-777 AND TRP-888, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=27467858; DOI=10.1002/humu.23057;
RA   Stella J., Buers I., van de Wetering K., Hoehne W., Rutsch F.,
RA   Nitschke Y.;
RT   "Effects of Different Variants in the ENPP1 Gene on the Functional
RT   Properties of Ectonucleotide Pyrophosphatase/Phosphodiesterase Family
RT   Member 1.";
RL   Hum. Mutat. 37:1190-1201(2016).
CC   -!- FUNCTION: By generating PPi, plays a role in regulating
CC       pyrophosphate levels, and functions in bone mineralization and
CC       soft tissue calcification. PPi inhibits mineralization by binding
CC       to nascent hydroxyapatite (HA) crystals, thereby preventing
CC       further growth of these crystals. Preferentially hydrolyzes ATP,
CC       but can also hydrolyze other nucleoside 5' triphosphates such as
CC       GTP, CTP, TTP and UTP to their corresponding monophosphates with
CC       release of pyrophosphate and diadenosine polyphosphates, and also
CC       3',5'-cAMP to AMP. May also be involved in the regulation of the
CC       availability of nucleotide sugars in the endoplasmic reticulum and
CC       Golgi, and the regulation of purinergic signaling. Appears to
CC       modulate insulin sensitivity and function.
CC       {ECO:0000269|PubMed:10615944, ECO:0000269|PubMed:27467858,
CC       ECO:0000269|PubMed:8001561}.
CC   -!- CATALYTIC ACTIVITY: Hydrolytically removes 5'-nucleotides
CC       successively from the 3'-hydroxy termini of 3'-hydroxy-terminated
CC       oligonucleotides. {ECO:0000269|PubMed:8001561}.
CC   -!- CATALYTIC ACTIVITY: A nucleoside triphosphate + H(2)O = a
CC       nucleotide + diphosphate. {ECO:0000269|PubMed:8001561}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P06802};
CC       Note=Binds 2 Zn(2+) ions per subunit.
CC       {ECO:0000250|UniProtKB:P06802};
CC   -!- ENZYME REGULATION: At low concentrations of ATP, a phosphorylated
CC       intermediate is formed which inhibits further hydrolysis.
CC   -!- SUBUNIT: The secreted form is monomeric (By similarity).
CC       Homodimer. Interacts with INSR. {ECO:0000250,
CC       ECO:0000269|PubMed:10615944}.
CC   -!- INTERACTION:
CC       P06213:INSR; NbExp=2; IntAct=EBI-3197846, EBI-475899;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:27467858};
CC       Single-pass type II membrane protein. Basolateral cell membrane;
CC       Single-pass type II membrane protein. Secreted {ECO:0000250}.
CC       Note=The proteolytically processed form is secreted (By
CC       similarity). Targeted to the basolateral membrane in polarized
CC       epithelial cells and in hepatocytes, and to matrix vesicles in
CC       osteoblasts. In bile duct cells and cancer cells, located to the
CC       apical cytoplasmic side. {ECO:0000250,
CC       ECO:0000269|PubMed:11598187, ECO:0000269|PubMed:15072822,
CC       ECO:0000269|PubMed:8001561}.
CC   -!- TISSUE SPECIFICITY: Expressed in plasma cells and also in a number
CC       of non-lymphoid tissues, including the distal convoluted tubule of
CC       the kidney, chondrocytes and epididymis.
CC       {ECO:0000269|PubMed:9344668}.
CC   -!- DOMAIN: The di-leucine motif is required for basolateral targeting
CC       in epithelial cells, and for targeting to matrix vesicles derived
CC       from mineralizing cells. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated as part of the catalytic cycle of
CC       phosphodiesterase/pyrophosphatase activity.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:8001561}.
CC   -!- PTM: A secreted form is produced through cleavage at Lys-103 by
CC       intracellular processing. {ECO:0000250|UniProtKB:P06802}.
CC   -!- DISEASE: Ossification of the posterior longitudinal ligament of
CC       the spine (OPLL) [MIM:602475]: A calcification of the posterior
CC       longitudinal ligament of the spinal column, usually at the level
CC       of the cervical spine. Patients with OPLL frequently present with
CC       a severe myelopathy that can lead to tetraparesis.
CC       {ECO:0000269|PubMed:10453738}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Arterial calcification of infancy, generalized, 1 (GACI1)
CC       [MIM:208000]: A severe autosomal recessive disorder characterized
CC       by calcification of the internal elastic lamina of muscular
CC       arteries and stenosis due to myointimal proliferation. The
CC       disorder is often fatal within the first 6 months of life because
CC       of myocardial ischemia resulting in refractory heart failure.
CC       {ECO:0000269|PubMed:12881724, ECO:0000269|PubMed:15605415,
CC       ECO:0000269|PubMed:15940697, ECO:0000269|PubMed:20016754,
CC       ECO:0000269|PubMed:22209248, ECO:0000269|PubMed:23430823,
CC       ECO:0000269|PubMed:27467858}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:16186408}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hypophosphatemic rickets, autosomal recessive, 2 (ARHR2)
CC       [MIM:613312]: A hereditary form of hypophosphatemic rickets, a
CC       disorder of proximal renal tubule function that causes phosphate
CC       loss, hypophosphatemia and skeletal deformities, including rickets
CC       and osteomalacia unresponsive to vitamin D. Symptoms are bone
CC       pain, fractures and growth abnormalities.
CC       {ECO:0000269|PubMed:20137772, ECO:0000269|PubMed:20137773,
CC       ECO:0000269|PubMed:25741938}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cole disease (COLED) [MIM:615522]: A rare autosomal
CC       dominant genodermatosis characterized by punctate keratoderma
CC       associated with irregularly shaped hypopigmented macules, which
CC       are typically found over the arms and legs but not the trunk or
CC       acral regions. Skin biopsies of palmoplantar lesions show
CC       hyperorthokeratosis, hypergranulosis, and acanthosis.
CC       Hypopigmented areas of skin, however, reveal a reduction in
CC       melanin content in keratinocytes but not in melanocytes, as well
CC       as hyperkeratosis and a normal number of melanocytes.
CC       Ultrastructurally, melanocytes show a disproportionately large
CC       number of melanosomes in the cytoplasm and dendrites, whereas
CC       keratinocytes show a paucity of these organelles, suggestive of
CC       impaired melanosome transfer. Some patients also exhibit
CC       calcinosis cutis or calcific tendinopathy.
CC       {ECO:0000269|PubMed:24075184, ECO:0000269|PubMed:26617416}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the nucleotide
CC       pyrophosphatase/phosphodiesterase family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-53 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA63237.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH59375.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA02054.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M57736; AAA63237.1; ALT_INIT; mRNA.
DR   EMBL; D12485; BAA02054.1; ALT_INIT; mRNA.
DR   EMBL; AF110304; AAF36094.1; -; Genomic_DNA.
DR   EMBL; AF110280; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110281; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110283; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110284; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110285; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110286; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110287; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110288; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110289; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110290; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110291; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110292; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110293; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110294; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110295; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110296; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110297; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110298; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110299; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110300; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110301; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110302; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AF110303; AAF36094.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242020; CAC39442.1; -; Genomic_DNA.
DR   EMBL; AJ242021; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242022; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242023; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242024; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242025; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242026; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242027; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242028; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242029; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242030; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242031; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242032; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242033; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242034; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242035; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242036; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242037; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242038; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242039; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242040; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242041; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242042; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242043; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AJ242044; CAC39442.1; JOINED; Genomic_DNA.
DR   EMBL; AL117378; CAI19514.1; -; Genomic_DNA.
DR   EMBL; AL139805; CAI19514.1; JOINED; Genomic_DNA.
DR   EMBL; AL139805; CAI20161.1; -; Genomic_DNA.
DR   EMBL; AL117378; CAI20161.1; JOINED; Genomic_DNA.
DR   EMBL; BC059375; AAH59375.2; ALT_INIT; mRNA.
DR   EMBL; AF067177; AAD38420.1; -; Genomic_DNA.
DR   EMBL; AF067178; AAD38421.1; -; Genomic_DNA.
DR   CCDS; CCDS5150.2; -.
DR   PIR; A39216; A39216.
DR   RefSeq; NP_006199.2; NM_006208.2.
DR   UniGene; Hs.527295; -.
DR   PDB; 2YS0; NMR; -; A=147-189.
DR   PDBsum; 2YS0; -.
DR   ProteinModelPortal; P22413; -.
DR   SMR; P22413; -.
DR   BioGrid; 111193; 10.
DR   IntAct; P22413; 4.
DR   STRING; 9606.ENSP00000354238; -.
DR   BindingDB; P22413; -.
DR   ChEMBL; CHEMBL5925; -.
DR   DrugBank; DB01143; Amifostine.
DR   DrugBank; DB00811; Ribavirin.
DR   iPTMnet; P22413; -.
DR   PhosphoSitePlus; P22413; -.
DR   BioMuta; ENPP1; -.
DR   DMDM; 23503088; -.
DR   EPD; P22413; -.
DR   MaxQB; P22413; -.
DR   PaxDb; P22413; -.
DR   PeptideAtlas; P22413; -.
DR   PRIDE; P22413; -.
DR   Ensembl; ENST00000360971; ENSP00000354238; ENSG00000197594.
DR   GeneID; 5167; -.
DR   KEGG; hsa:5167; -.
DR   UCSC; uc011ecf.2; human.
DR   CTD; 5167; -.
DR   DisGeNET; 5167; -.
DR   GeneCards; ENPP1; -.
DR   HGNC; HGNC:3356; ENPP1.
DR   HPA; CAB032904; -.
DR   HPA; HPA062066; -.
DR   MalaCards; ENPP1; -.
DR   MIM; 125853; phenotype.
DR   MIM; 173335; gene.
DR   MIM; 208000; phenotype.
DR   MIM; 602475; phenotype.
DR   MIM; 613312; phenotype.
DR   MIM; 615522; phenotype.
DR   neXtProt; NX_P22413; -.
DR   OpenTargets; ENSG00000197594; -.
DR   Orphanet; 289176; Autosomal recessive hypophosphatemic rickets.
DR   Orphanet; 51608; Generalized arterial calcification of infancy.
DR   Orphanet; 324561; Hypopigmentation-punctate palmoplantar keratoderma syndrome.
DR   PharmGKB; PA27791; -.
DR   eggNOG; KOG2645; Eukaryota.
DR   eggNOG; COG1524; LUCA.
DR   GeneTree; ENSGT00760000119157; -.
DR   HOGENOM; HOG000037439; -.
DR   HOVERGEN; HBG051484; -.
DR   InParanoid; P22413; -.
DR   KO; K01513; -.
DR   OMA; NIVPMYQ; -.
DR   OrthoDB; EOG091G017X; -.
DR   PhylomeDB; P22413; -.
DR   TreeFam; TF330032; -.
DR   BRENDA; 3.6.1.9; 2681.
DR   Reactome; R-HSA-196843; Vitamin B2 (riboflavin) metabolism.
DR   Reactome; R-HSA-199220; Vitamin B5 (pantothenate) metabolism.
DR   SABIO-RK; P22413; -.
DR   EvolutionaryTrace; P22413; -.
DR   GeneWiki; Ectonucleotide_pyrophosphatase/phosphodiesterase_1; -.
DR   GenomeRNAi; 5167; -.
DR   PRO; PR:P22413; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000197594; -.
DR   CleanEx; HS_ENPP1; -.
DR   ExpressionAtlas; P22413; baseline and differential.
DR   Genevisible; P22413; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; NAS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0050656; F:3'-phosphoadenosine 5'-phosphosulfate binding; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0035529; F:NADH pyrophosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0047429; F:nucleoside-triphosphate diphosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0004551; F:nucleotide diphosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0004528; F:phosphodiesterase I activity; IDA:UniProtKB.
DR   GO; GO:0030247; F:polysaccharide binding; IEA:InterPro.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0050427; P:3'-phosphoadenosine 5'-phosphosulfate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0031214; P:biomineral tissue development; IEA:UniProtKB-KW.
DR   GO; GO:0030643; P:cellular phosphate ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; IDA:BHF-UCL.
DR   GO; GO:0006955; P:immune response; IEA:InterPro.
DR   GO; GO:0030505; P:inorganic diphosphate transport; IDA:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0046325; P:negative regulation of glucose import; IDA:BHF-UCL.
DR   GO; GO:0045719; P:negative regulation of glycogen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0031953; P:negative regulation of protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0009143; P:nucleoside triphosphate catabolic process; IDA:BHF-UCL.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; IDA:BHF-UCL.
DR   GO; GO:0030500; P:regulation of bone mineralization; IC:BHF-UCL.
DR   GO; GO:0006771; P:riboflavin metabolic process; TAS:Reactome.
DR   GO; GO:0030730; P:sequestering of triglyceride; IDA:BHF-UCL.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR001604; DNA/RNA_non-sp_Endonuclease.
DR   InterPro; IPR029890; ENPP1.
DR   InterPro; IPR020821; Extracellular_endonuc_su_A.
DR   InterPro; IPR002591; Phosphodiest/P_Trfase.
DR   InterPro; IPR020436; Somatomedin_B_chordata.
DR   InterPro; IPR001212; Somatomedin_B_dom.
DR   PANTHER; PTHR10151:SF84; PTHR10151:SF84; 1.
DR   Pfam; PF01223; Endonuclease_NS; 1.
DR   Pfam; PF01663; Phosphodiest; 1.
DR   Pfam; PF01033; Somatomedin_B; 2.
DR   PRINTS; PR00022; SOMATOMEDINB.
DR   SMART; SM00892; Endonuclease_NS; 1.
DR   SMART; SM00477; NUC; 1.
DR   SMART; SM00201; SO; 2.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   SUPFAM; SSF90188; SSF90188; 2.
DR   PROSITE; PS00524; SMB_1; 2.
DR   PROSITE; PS50958; SMB_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Biomineralization; Calcium; Cell membrane;
KW   Complete proteome; Diabetes mellitus; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hydrolase; Membrane;
KW   Metal-binding; Obesity; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Secreted; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   CHAIN         1    925       Ectonucleotide
FT                                pyrophosphatase/phosphodiesterase family
FT                                member 1.
FT                                /FTId=PRO_0000188564.
FT   TOPO_DOM      1     76       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     77     97       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     98    925       Extracellular. {ECO:0000255}.
FT   DOMAIN      104    144       SMB 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   DOMAIN      145    189       SMB 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   REGION      191    591       Phosphodiesterase.
FT   REGION      597    647       Linker. {ECO:0000250}.
FT   REGION      654    925       Nuclease.
FT   MOTIF        45     52       Di-leucine motif.
FT   ACT_SITE    256    256       AMP-threonine intermediate.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       218    218       Zinc 1; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       256    256       Zinc 1; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       376    376       Zinc 2; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       380    380       Zinc 2; via tele nitrogen; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       423    423       Zinc 1; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       424    424       Zinc 1; via tele nitrogen; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       535    535       Zinc 2; via tele nitrogen; catalytic.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       800    800       Calcium. {ECO:0000250|UniProtKB:P06802}.
FT   METAL       802    802       Calcium. {ECO:0000250|UniProtKB:P06802}.
FT   METAL       804    804       Calcium. {ECO:0000250|UniProtKB:P06802}.
FT   METAL       806    806       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   METAL       808    808       Calcium. {ECO:0000250|UniProtKB:P06802}.
FT   BINDING     277    277       Substrate.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   BINDING     295    295       Substrate.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   BINDING     340    340       Substrate.
FT                                {ECO:0000250|UniProtKB:P06802}.
FT   SITE        102    103       Cleavage. {ECO:0000250|UniProtKB:P06802}.
FT   SITE        915    915       Essential for catalytic activity.
FT                                {ECO:0000250}.
FT   MOD_RES     256    256       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q924C3}.
FT   CARBOHYD    179    179       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    285    285       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    341    341       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    477    477       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    585    585       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    643    643       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    700    700       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    731    731       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    748    748       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   DISULFID    108    122       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    112    140       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    120    133       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    126    132       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    149    166       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    154    184       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    164    177       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    170    176       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    195    241       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    203    415       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    431    530       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    480    868       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    614    672       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    626    726       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    628    711       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    838    848       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   VARIANT      91     91       L -> P (in OPLL).
FT                                {ECO:0000269|PubMed:10453738}.
FT                                /FTId=VAR_014141.
FT   VARIANT      92     92       G -> D (in ARHR2).
FT                                {ECO:0000269|PubMed:25741938}.
FT                                /FTId=VAR_077255.
FT   VARIANT     126    126       C -> R (in GACI1).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077256.
FT   VARIANT     133    133       C -> R (in COLED).
FT                                {ECO:0000269|PubMed:26617416}.
FT                                /FTId=VAR_077257.
FT   VARIANT     149    149       C -> S (in COLED; dbSNP:rs397518477).
FT                                {ECO:0000269|PubMed:24075184}.
FT                                /FTId=VAR_070782.
FT   VARIANT     164    164       C -> S (in COLED; dbSNP:rs397518476).
FT                                {ECO:0000269|PubMed:24075184}.
FT                                /FTId=VAR_070783.
FT   VARIANT     173    173       K -> Q (polymorphism; associated with
FT                                NIDDM; decreased nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs1044498).
FT                                {ECO:0000269|PubMed:10453738,
FT                                ECO:0000269|PubMed:10480624,
FT                                ECO:0000269|PubMed:16186408,
FT                                ECO:0000269|PubMed:20034067,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_008873.
FT   VARIANT     177    177       C -> S (in COLED).
FT                                {ECO:0000269|PubMed:26617416}.
FT                                /FTId=VAR_077258.
FT   VARIANT     177    177       C -> Y (in COLED; dbSNP:rs397518475).
FT                                {ECO:0000269|PubMed:24075184}.
FT                                /FTId=VAR_070784.
FT   VARIANT     179    179       N -> S (in dbSNP:rs2273411).
FT                                /FTId=VAR_037432.
FT   VARIANT     195    195       C -> R (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; loss of
FT                                localization to plasma membrane;
FT                                dbSNP:rs763457176).
FT                                {ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077259.
FT   VARIANT     195    195       C -> S (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; loss of
FT                                localization to plasma membrane).
FT                                {ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077260.
FT   VARIANT     216    216       S -> Y (in GACI1; unknown pathological
FT                                significance; dbSNP:rs760786509).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077261.
FT   VARIANT     218    218       D -> V (in GACI1).
FT                                {ECO:0000269|PubMed:23430823}.
FT                                /FTId=VAR_077262.
FT   VARIANT     219    219       G -> R (in ARHR2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25741938}.
FT                                /FTId=VAR_077263.
FT   VARIANT     242    242       G -> E (in GACI1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077264.
FT   VARIANT     250    250       P -> L (in GACI1; unknown pathological
FT                                significance; dbSNP:rs754659608).
FT                                {ECO:0000269|PubMed:15605415,
FT                                ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_067910.
FT   VARIANT     252    252       Missing (in GACI1).
FT                                {ECO:0000269|PubMed:15605415}.
FT                                /FTId=VAR_067911.
FT   VARIANT     266    266       G -> V (in ARHR2; dbSNP:rs121908248).
FT                                {ECO:0000269|PubMed:20137773}.
FT                                /FTId=VAR_063719.
FT   VARIANT     268    268       Y -> H (in dbSNP:rs17847050).
FT                                {ECO:0000269|PubMed:10453738}.
FT                                /FTId=VAR_014142.
FT   VARIANT     276    276       D -> N (in GACI1; unknown pathological
FT                                significance; dbSNP:rs143771474).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077265.
FT   VARIANT     287    287       S -> F (in OPLL; dbSNP:rs190947144).
FT                                {ECO:0000269|PubMed:10453738}.
FT                                /FTId=VAR_014143.
FT   VARIANT     301    301       Y -> C (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; loss of
FT                                localization to plasma membrane).
FT                                {ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077266.
FT   VARIANT     305    305       P -> T (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs374270497).
FT                                {ECO:0000269|PubMed:15605415,
FT                                ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_067912.
FT   VARIANT     342    342       G -> V (in GACI1; dbSNP:rs121918025).
FT                                {ECO:0000269|PubMed:15605415,
FT                                ECO:0000269|PubMed:15940697,
FT                                ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_037433.
FT   VARIANT     349    349       R -> K (in GACI1; unknown pathological
FT                                significance; dbSNP:rs764735802).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077267.
FT   VARIANT     371    371       Y -> F (in GACI1; unknown pathological
FT                                significance; dbSNP:rs121918026).
FT                                {ECO:0000269|PubMed:15605415,
FT                                ECO:0000269|PubMed:15940697,
FT                                ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_037434.
FT   VARIANT     456    456       R -> Q (in GACI1; dbSNP:rs765071179).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077268.
FT   VARIANT     471    471       Y -> C (in GACI1; decreased nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs148462924).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077269.
FT   VARIANT     481    481       R -> W (in GACI1; unknown pathological
FT                                significance; dbSNP:rs373044722).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077270.
FT   VARIANT     500    500       H -> P (in GACI1).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077271.
FT   VARIANT     504    504       S -> R (in GACI1; decreased nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077272.
FT   VARIANT     513    513       Y -> C (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077273.
FT   VARIANT     538    538       D -> H (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs387906673).
FT                                {ECO:0000269|PubMed:22209248,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_067913.
FT   VARIANT     570    570       Y -> C (in GACI1; dbSNP:rs140248167).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077274.
FT   VARIANT     579    579       L -> F (in GACI1; unknown pathological
FT                                significance; dbSNP:rs121918024).
FT                                {ECO:0000269|PubMed:12881724,
FT                                ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_018514.
FT   VARIANT     586    586       G -> R (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; loss of
FT                                localization to plasma membrane).
FT                                {ECO:0000269|PubMed:22209248,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_067914.
FT   VARIANT     611    611       L -> V (in dbSNP:rs79079368).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077275.
FT   VARIANT     659    659       Y -> C (in GACI1; decreased nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs143393727).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077276.
FT   VARIANT     668    668       E -> K (polymorphism; no effect on
FT                                nucleotide phosphodiesterase activity; no
FT                                effect on localization to plasma
FT                                membrane; dbSNP:rs115371819).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077277.
FT   VARIANT     726    726       C -> R (in GACI1).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077278.
FT   VARIANT     774    774       R -> C (polymorphism; decreased
FT                                nucleotide phosphodiesterase activity; no
FT                                effect on localization to plasma
FT                                membrane; dbSNP:rs28933977).
FT                                {ECO:0000269|PubMed:12881724,
FT                                ECO:0000269|PubMed:15605415,
FT                                ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_018515.
FT   VARIANT     777    777       H -> R (in GACI1; decreased nucleotide
FT                                phosphodiesterase activity; no effect on
FT                                localization to plasma membrane;
FT                                dbSNP:rs147346173).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077279.
FT   VARIANT     779    779       T -> P (in dbSNP:rs1805138).
FT                                {ECO:0000269|PubMed:10453738}.
FT                                /FTId=VAR_014144.
FT   VARIANT     792    792       N -> S (in ARHR2 and GACI1;
FT                                dbSNP:rs370184526).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:25741938}.
FT                                /FTId=VAR_077280.
FT   VARIANT     804    804       D -> H (in GACI1).
FT                                {ECO:0000269|PubMed:20016754}.
FT                                /FTId=VAR_077281.
FT   VARIANT     821    821       R -> H (polymorphism; decreased
FT                                nucleotide phosphodiesterase activity; no
FT                                effect on localization to plasma
FT                                membrane; dbSNP:rs367759638).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077282.
FT   VARIANT     886    886       R -> T (in dbSNP:rs8192683).
FT                                /FTId=VAR_037435.
FT   VARIANT     888    888       R -> W (in GACI1; loss of nucleotide
FT                                phosphodiesterase activity; loss of
FT                                localization to plasma membrane;
FT                                dbSNP:rs184483616).
FT                                {ECO:0000269|PubMed:20016754,
FT                                ECO:0000269|PubMed:27467858}.
FT                                /FTId=VAR_077283.
FT   VARIANT     901    901       Y -> S (in ARHR2; loss of activity;
FT                                dbSNP:rs121908249).
FT                                {ECO:0000269|PubMed:20137772}.
FT                                /FTId=VAR_063720.
FT   TURN        151    155       {ECO:0000244|PDB:2YS0}.
FT   STRAND      163    165       {ECO:0000244|PDB:2YS0}.
FT   HELIX       168    173       {ECO:0000244|PDB:2YS0}.
FT   HELIX       180    183       {ECO:0000244|PDB:2YS0}.
SQ   SEQUENCE   925 AA;  104924 MW;  0ECAA063801CAFEB CRC64;
     MERDGCAGGG SRGGEGGRAP REGPAGNGRD RGRSHAAEAP GDPQAAASLL APMDVGEEPL
     EKAARARTAK DPNTYKVLSL VLSVCVLTTI LGCIFGLKPS CAKEVKSCKG RCFERTFGNC
     RCDAACVELG NCCLDYQETC IEPEHIWTCN KFRCGEKRLT RSLCACSDDC KDKGDCCINY
     SSVCQGEKSW VEEPCESINE PQCPAGFETP PTLLFSLDGF RAEYLHTWGG LLPVISKLKK
     CGTYTKNMRP VYPTKTFPNH YSIVTGLYPE SHGIIDNKMY DPKMNASFSL KSKEKFNPEW
     YKGEPIWVTA KYQGLKSGTF FWPGSDVEIN GIFPDIYKMY NGSVPFEERI LAVLQWLQLP
     KDERPHFYTL YLEEPDSSGH SYGPVSSEVI KALQRVDGMV GMLMDGLKEL NLHRCLNLIL
     ISDHGMEQGS CKKYIYLNKY LGDVKNIKVI YGPAARLRPS DVPDKYYSFN YEGIARNLSC
     REPNQHFKPY LKHFLPKRLH FAKSDRIEPL TFYLDPQWQL ALNPSERKYC GSGFHGSDNV
     FSNMQALFVG YGPGFKHGIE ADTFENIEVY NLMCDLLNLT PAPNNGTHGS LNHLLKNPVY
     TPKHPKEVHP LVQCPFTRNP RDNLGCSCNP SILPIEDFQT QFNLTVAEEK IIKHETLPYG
     RPRVLQKENT ICLLSQHQFM SGYSQDILMP LWTSYTVDRN DSFSTEDFSN CLYQDFRIPL
     SPVHKCSFYK NNTKVSYGFL SPPQLNKNSS GIYSEALLTT NIVPMYQSFQ VIWRYFHDTL
     LRKYAEERNG VNVVSGPVFD FDYDGRCDSL ENLRQKRRVI RNQEILIPTH FFIVLTSCKD
     TSQTPLHCEN LDTLAFILPH RTDNSESCVH GKHDSSWVEE LLMLHRARIT DVEHITGLSF
     YQQRKEPVSD ILKLKTHLPT FSQED
//
